ASCJ Compounds are in pre-clinical tests for the following indications:
Currently, our lead compound (ASCJ-9) is being developed
as a topical treatment for acne and male pattern baldness (androgenetic
alopecia)
ASCJ-M5 compound is in the pre-development stage
for oral drugs to treat prostate cancer and BPH
Our ASCJ-15 compound is in line as a topical treatment
for wound healing.
ASCJ compounds are derived from natural products that appear to have a unique mechanism of action, i.e.,
by enhancing degradation of androgen receptors (ARD enhancer). These compounds have shown good activity
in vitro and in vivo and their potency has been validated in preclinical animal models for acne, alopecia, and
prostate cancer. Currently, AndroScience is conducting GLP toxicology and accumulating other preclinical data in
order to file an IND and proceed to Phase I and II clinical studies.
New Product Development
AndroScience has received three SBIR grants awarded from NIH to support its drug development projects,
which include: 1) the development of a natural product screening platform; 2) study the action mechanism of
AR degradation enhancers; 3) treatment of acne using AR degradation enhancers.
